FDA set to review Sandoz generic GLP-1 applications, Reuters reports
Generic entry would change pricing and supply dynamics that currently drive compounded semaglutide demand.
DO
By Daniel Okafor · Regulatory Correspondent
Jun 29 03:00 ETSource: Reuters
The wire
- 01Reuters reports the FDA is preparing to review generic GLP-1 applications from Sandoz.
- 02Approved generics would give pharmacies and prescribers a lower-cost legal alternative to branded incretins and to gray-market compounded copies.
- 03Review timing, which molecules are covered and any patent litigation that could delay launch are not specified.
From the source
Read at reuters.comFDA set to review Sandoz's generic GLP-1s
